Progress in Cardiovascular Diseases
Volume 52, Issue 5 , Pages 410-428 , March 2010

Matrix Metalloproteinases in Atherothrombosis

  • Magnus Bäck

      Affiliations

    • Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden
    • Department of Medicine, Karolinska Institutet, Stockholm, Sweden
    • Corresponding Author InformationAddress reprint requests to Magnus Bäck, MD, PhD, Karolinska University Hospital, CMM L8:03, 171 76 Stockholm, Sweden and Stefan Agewall MD, PhD, University of Oslo, 0514 Oslo, Norway.
    • ,
  • Daniel F.J. Ketelhuth

      Affiliations

    • Department of Medicine, Karolinska Institutet, Stockholm, Sweden
    • ,
  • Stefan Agewall

      Affiliations

    • Department of Medicine, Aker University Hospital and Oslo University, Oslo, Norway
    • Corresponding Author InformationAddress reprint requests to Magnus Bäck, MD, PhD, Karolinska University Hospital, CMM L8:03, 171 76 Stockholm, Sweden and Stefan Agewall MD, PhD, University of Oslo, 0514 Oslo, Norway.

References 

  1. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657–671
  2. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007;8:221–233
  3. Newby AC. Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and non-matrix substrates. Cardiovasc Res. 2006;69:614–624
  4. Guo H, Zucker S, Gordon MK, et al. Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells. J Biol Chem. 1997;272:24–27
  5. Huang Y, Mironova M, Lopes-Virella MF. Oxidized LDL stimulates matrix metalloproteinase-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol. 1999;19:2640–2647
  6. Spiegel S, Foster D, Kolesnick R. Signal transduction through lipid second messengers. Curr Opin Cell Biol. 1996;8:159–167
  7. Reunanen N, Westermarck J, Hakkinen L, et al. Enhancement of fibroblast collagenase (matrix metalloproteinase-1) gene expression by ceramide is mediated by extracellular signal-regulated and stress-activated protein kinase pathways. J Biol Chem. 1998;273:5137–5145
  8. Ye S, Gale CR, Martyn CN. Variation in the matrix metalloproteinase-1 gene and risk of coronary heart disease. Eur Heart J. 2003;24:1668–1671
  9. Ghilardi G, Biondi ML, DeMonti M, et al. Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with carotid artery stenosis. Stroke. 2002;33:2408–2412
  10. Pearce E, Tregouet DA, Samnegard A, et al. Haplotype effect of the matrix metalloproteinase-1 gene on risk of myocardial infarction. Circ Res. 2005;97:1070–1076
  11. Inoue T, Kato T, Takayanagi K, et al. Circulating matrix metalloproteinase-1 and -3 in patients with an acute coronary syndrome. Am J Cardiol. 2003;92:1461–1464
  12. Kato R, Momiyama Y, Ohmori R, et al. Levels of matrix metalloproteinase-1 in patients with and without coronary artery disease and relation to complex and noncomplex coronary plaques. Am J Cardiol. 2005;95:90–92
  13. Hwang JJ, Yang WS, Chiang FT, et al. Association of circulating matrix metalloproteinase-1, but not adiponectin, with advanced coronary artery disease. Atherosclerosis. 2009;204:293–297
  14. Wu YW, Yang WS, Chen MF, et al. High serum level of matrix metalloproteinase-1 and its rapid surge after intervention in patients with significant carotid atherosclerosis. J Formos Med Assoc. 2008;107:93–98
  15. Samnegard A, Hulthe J, Silveira A, et al. Gender specific associations between matrix metalloproteinases and inflammatory markers in post myocardial infarction patients. Atherosclerosis. 2009;202:550–556
  16. Horwitz AL, Hance AJ, Crystal RG. Granulocyte collagenase: selective digestion of type I relative to type III collagen. Proc Natl Acad Sci U S A. 1977;74:897–901
  17. Laxton RC, Hu Y, Duchene J, et al. A role of matrix metalloproteinase-8 in atherosclerosis. Circ Res. 2009;
  18. Kusano K, Miyaura C, Inada M, et al. Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology. 1998;139:1338–1345
  19. Turu MM, Krupinski J, Catena E, et al. Intraplaque MMP-8 levels are increased in asymptomatic patients with carotid plaque progression on ultrasound. Atherosclerosis. 2006;187:161–169
  20. Kato R, Momiyama Y, Ohmori R, et al. Plasma matrix metalloproteinase-8 concentrations are associated with the presence and severity of coronary artery disease. Circ J. 2005;69:1035–1040
  21. Tuomainen AM, Nyyssonen K, Laukkanen JA, et al. Serum matrix metalloproteinase-8 concentrations are associated with cardiovascular outcome in men. Arterioscler Thromb Vasc Biol. 2007;27:2722–2728
  22. Knauper V, Lopez-Otin C, Smith B, et al. Biochemical characterization of human collagenase-3. J Biol Chem. 1996;271:1544–1550
  23. Deguchi JO, Aikawa E, Libby P, et al. Matrix metalloproteinase-13/collagenase-3 deletion promotes collagen accumulation and organization in mouse atherosclerotic plaques. Circulation. 2005;112:2708–2715
  24. Pourmotabbed T. Relation between substrate specificity and domain structure of 92-kDa type IV collagenase. Ann N Y Acad Sci. 1994;732:372–374
  25. Pourmotabbed T, Solomon TL, Hasty KA, et al. Characteristics of 92 kDa type IV collagenase/gelatinase produced by granulocytic leukemia cells: structure, expression of cDNA in E. coli and enzymic properties. Biochim Biophys Acta. 1994;1204:97–107
  26. Senior RM, Griffin GL, Fliszar CJ, et al. Human 92-and 72-kilodalton type IV collagenases are elastases. J Biol Chem. 1991;266:7870–7875
  27. McQuibban GA, Butler GS, Gong JH, et al. Matrix metalloproteinase activity inactivates the CXC chemokine stromal cell-derived factor-1. J Biol Chem. 2001;276:43503–43508
  28. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000;14:163–176
  29. Gearing AJ, Beckett P, Christodoulou M, et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature. 1994;370:555–557
  30. Schonbeck U, Mach F, Libby P. Generation of biologically active IL-1 beta by matrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 beta processing. J Immunol. 1998;161:3340–3346
  31. Fernandez-Patron C, Radomski MW, Davidge ST. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res. 1999;85:906–911
  32. Bäck M. Leukotriene signaling in atherosclerosis and ischemia. Cardiovasc Drugs Ther. 2009;23:41–48
  33. Cipollone F, Mezzetti A, Fazia ML, et al. Association between 5-lipoxygenase expression and plaque instability in humans. Arterioscler Thromb Vasc Biol. 2005;25:1665–1670
  34. Hlawaty H, Jacob MP, Louedec L, et al. Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis. Arterioscler Thromb Vasc Biol. 2009;29:518–524
  35. Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 2001;103:926–933
  36. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol. 2003;23:769–775
  37. Hua Y, Xue J, Sun F, et al. Aspirin inhibits MMP-2 and MMP-9 expressions and activities through upregulation of PPARalpha/gamma and TIMP gene expressions in ox-LDL-stimulated macrophages derived from human monocytes. Pharmacology. 2009;83:18–25
  38. Bea F, Kreuzer J, Preusch M, et al. Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2006;26:2787–2792
  39. Vasku A, Goldbergova M, Izakovicova Holla L, et al. A haplotype constituted of four MMP-2 promoter polymorphisms (-1575G/A, -1306C/T, -790T/G and -735C/T) is associated with coronary triple-vessel disease. Matrix Biol. 2004;22:585–591
  40. Kai H, Ikeda H, Yasukawa H, et al. Peripheral blood levels of matrix metalloproteases-2 and-9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol. 1998;32:368–372
  41. Alvarez B, Ruiz C, Chacon P, et al. Serum values of metalloproteinase-2 and metalloproteinase-9 as related to unstable plaque and inflammatory cells in patients with greater than 70% carotid artery stenosis. J Vasc Surg. 2004;40:469–475
  42. Taurino M, Raffa S, Mastroddi M, et al. Metalloproteinase expression in carotid plaque and its correlation with plasma levels before and after carotid endarterectomy. Vasc Endovascular Surg. 2007;41:516–521
  43. Morodomi T, Ogata Y, Sasaguri Y, et al. Purification and characterization of matrix metalloproteinase 9 from U937 monocytic leukaemia and HT1080 fibrosarcoma cells. Biochem J. 1992;285(Pt 2):603–611
  44. Fosang AJ, Neame PJ, Last K, et al. The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J Biol Chem. 1992;267:19470–19474
  45. Kenny HA, Kaur S, Coussens LM, et al. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. J Clin Invest. 2008;118:1367–1379
  46. Van den Steen PE, Proost P, Wuyts A, et al. Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. Blood. 2000;96:2673–2681
  47. Blankenberg S, Rupprecht HJ, Poirier O, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation. 2003;107:1579–1585
  48. Morgan AR, Zhang B, Tapper W, et al. Haplotypic analysis of the MMP-9 gene in relation to coronary artery disease. J Mol Med. 2003;81:321–326
  49. Zhang B, Ye S, Herrmann SM, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation. 1999;99:1788–1794
  50. Pollanen PJ, Karhunen PJ, Mikkelsson J, et al. Coronary artery complicated lesion area is related to functional polymorphism of matrix metalloproteinase 9 gene: an autopsy study. Arterioscler Thromb Vasc Biol. 2001;21:1446–1450
  51. Flex A, Gaetani E, Angelini F, et al. Pro-inflammatory genetic profiles in subjects with peripheral arterial occlusive disease and critical limb ischemia. J Intern Med. 2007;262:124–130
  52. Fiotti N, Altamura N, Fisicaro M, et al. P-9 microsatellite polymorphism: association with the progression of intima-media thickening and constrictive remodeling of carotid atherosclerotic plaques. Atherosclerosis. 2005;182:287–292
  53. Ferroni P, Basili S, Martini F, et al. Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. J Investig Med. 2003;51:295–300
  54. Tziakas DN, Chalikias GK, Hatzinikolaou EI, et al. Alteplase treatment affects circulating matrix metalloproteinase concentrations in patients with ST segment elevation acute myocardial infarction. Thromb Res. 2006;118:221–227
  55. Renko J, Kalela A, Jaakkola O, et al. Serum matrix metalloproteinase-9 is elevated in men with a history of myocardial infarction. Scand J Clin Lab Invest. 2004;64:255–261
  56. Kalela A, Koivu TA, Sisto T, et al. Serum matrix metalloproteinase-9 concentration in angiographically assessed coronary artery disease. Scand J Clin Lab Invest. 2002;62:337–342
  57. Olson FJ, Schmidt C, Gummesson A, et al. Circulating matrix metalloproteinase 9 levels in relation to sampling methods, femoral and carotid atherosclerosis. J Intern Med. 2008;263:626–635
  58. Fitzsimmons PJ, Forough R, Lawrence ME, et al. Urinary levels of matrix metalloproteinase 9 and 2 and tissue inhibitor of matrix metalloproteinase in patients with coronary artery disease. Atherosclerosis. 2007;194:196–203
  59. Okada Y, Nagase H, Harris ED, metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components A. Purification and characterization. J Biol Chem. 1986;261:14245–14255
  60. Lijnen HR, Silence J, Van Hoef B, et al. Stromelysin-1 (MMP-3)-independent gelatinase expression and activation in mice. Blood. 1998;91:2045–2053
  61. Nakamura H, Fujii Y, Ohuchi E, et al. Activation of the precursor of human stromelysin 2 and its interactions with other matrix metalloproteinases. Eur J Biochem. Apr 1. 1998;253:67–75
  62. Agnihotri R, Crawford HC, Haro H, et al. Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1) and matrix metalloproteinase-7 (matrilysin). J Biol Chem. 2001;276:28261–28267
  63. Gearing AJ, Beckett P, Christodoulou M, et al. Matrix metalloproteinases and processing of pro-TNF-alpha. J Leukoc Biol. 1995;57:774–777
  64. Leco KJ, Khokha R, Pavloff N, et al. Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J Biol Chem. 1994;269:9352–9360
  65. Saus J, Quinones S, Otani Y, et al. The complete primary structure of human matrix metalloproteinase-3. Identity with stromelysin. J Biol Chem. 1988;263:6742–6745
  66. Quinones S, Saus J, Otani Y, et al. Transcriptional regulation of human stromelysin. J Biol Chem. 1989;264:8339–8344
  67. Diaz-Meco MT, Quinones S, Municio MM, et al. Protein kinase C-independent expression of stromelysin by platelet-derived growth factor, ras oncogene, and phosphatidylcholine-hydrolyzing phospholipase C. J Biol Chem. 1991;266:22597–22602
  68. Kerr LD, Miller DB, Matrisian LM. TGF-beta 1 inhibition of transin/stromelysin gene expression is mediated through a Fos binding sequence. Cell. 1990;61:267–278
  69. Welgus HG, Campbell EJ, Cury JD, et al. Neutral metalloproteinases produced by human mononuclear phagocytes. Enzyme profile, regulation, and expression during cellular development. J Clin Invest. 1990;86:1496–1502
  70. Campbell EJ, Cury JD, Shapiro SD, et al. Neutral proteinases of human mononuclear phagocytes. Cellular differentiation markedly alters cell phenotype for serine proteinases, metalloproteinases, and tissue inhibitor of metalloproteinases. J Immunol. 1991;146:1286–1293
  71. Bar-Or A, Nuttall RK, Duddy M, et al. Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis. Brain. 2003;126(Pt 12):2738–2749
  72. Ye S, Watts GF, Mandalia S, et al. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J. 1995;73:209–215
  73. Humphries SE, Luong LA, Talmud PJ, et al. The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography Trial. Atherosclerosis. 1998;139:49–56
  74. Humphries SE, Martin S, Cooper J, et al. Interaction between smoking and the stromelysin-1 (MMP3) gene 5A/6A promoter polymorphism and risk of coronary heart disease in healthy men. Ann Hum Genet. 2002;66(Pt 5-6):343–352
  75. Hirashiki A, Yamada Y, Murase Y, et al. Association of gene polymorphisms with coronary artery disease in low-or high-risk subjects defined by conventional risk factors. J Am Coll Cardiol. 2003;42:1429–1437
  76. Gnasso A, Motti C, Irace C, et al. Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects. Arterioscler Thromb Vasc Biol. 2000;20:1600–1605
  77. Rauramaa R, Vaisanen SB, Luong LA, et al. Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol. 2000;20:2657–2662
  78. Rundek T, Elkind MS, Pittman J, et al. Carotid intima-media thickness is associated with allelic variants of stromelysin-1, interleukin-6, and hepatic lipase genes: the Northern Manhattan Prospective Cohort Study. Stroke. 2002;33:1420–1423
  79. Terashima M, Akita H, Kanazawa K, et al. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation. 1999;99:2717–2719
  80. Beyzade S, Zhang S, Wong YK, et al. Influences of matrix metalloproteinase-3 gene variation on extent of coronary atherosclerosis and risk of myocardial infarction. J Am Coll Cardiol. 2003;41:2130–2137
  81. Liu PY, Li YH, Chan SH, et al. Genotype-phenotype association of matrix metalloproteinase-3 polymorphism and its synergistic effect with smoking on the occurrence of acute coronary syndrome. Am J Cardiol. 2006;98:1012–1017
  82. Johnson JL, George SJ, Newby AC, et al. Divergent effects of matrix metalloproteinases 3, 7, 9, and 12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci U S A. 2005;102:15575–15580
  83. Silence J, Lupu F, Collen D, et al. Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol. 2001;21:1440–1445
  84. Gurbel PA, Kreutz RP, Bliden KP, et al. Biomarker analysis by fluorokine multianalyte profiling distinguishes patients requiring intervention from patients with long-term quiescent coronary artery disease: a potential approach to identify atherosclerotic disease progression. Am Heart J. 2008;155:56–61
  85. Nilsson L, Jonasson L, Nijm J, et al. Increased plasma concentration of matrix metalloproteinase-7 in patients with coronary artery disease. Clin Chem. 2006;52:1522–1527
  86. Samnegard A, Silveira A, Tornvall P, et al. Lower serum concentration of matrix metalloproteinase-3 in the acute stage of myocardial infarction. J Intern Med. 2006;259:530–536
  87. Kelly D, Khan S, Cockerill G, et al. Circulating stromelysin-1 (MMP-3): a novel predictor of LV dysfunction, remodelling and all-cause mortality after acute myocardial infarction. Eur J Heart Fail. 2008;10:133–139
  88. Rodriguez JA, Orbe J, Martinez de Lizarrondo S, et al. Metalloproteinases and atherothrombosis: MMP-10 mediates vascular remodeling promoted by inflammatory stimuli. Front Biosci. 2008;13:2916–2921
  89. Orbe J, Montero I, Rodriguez JA, et al. Independent association of matrix metalloproteinase-10, cardiovascular risk factors and subclinical atherosclerosis. J Thromb Haemost. 2007;5:91–97
  90. Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem. 1994;269:15957–15960
  91. Manes S, Mira E, Barbacid MM, et al. Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3. J Biol Chem. 1997;272:25706–25712
  92. Pei D, Weiss SJ. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature. 1995;375:244–247
  93. Lijnen HR, Van Hoef B, Vanlinthout I, et al. Accelerated neointima formation after vascular injury in mice with stromelysin-3 (MMP-11) gene inactivation. Arterioscler Thromb Vasc Biol. 1999;19:2863–2870
  94. Halpert I, Sires UI, Roby JD, et al. Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci U S A. 1996;93:9748–9753
  95. Sires UI, Griffin GL, Broekelmann TJ, et al. Degradation of entactin by matrix metalloproteinases. Susceptibility to matrilysin and identification of cleavage sites. J Biol Chem. 1993;268:2069–2074
  96. Imai K, Yokohama Y, Nakanishi I, et al. Matrix metalloproteinase 7 (matrilysin) from human rectal carcinoma cells. Activation of the precursor, interaction with other matrix metalloproteinases and enzymic properties. J Biol Chem. 1995;270:6691–6697
  97. Crabbe T, Smith B, O'Connell J, et al. Human progelatinase A can be activated by matrilysin. FEBS Lett. 1994;345:14–16
  98. Haro H, Crawford HC, Fingleton B, et al. Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J Clin Invest. 2000;105:143–150
  99. Lindsey ML, Escobar GP, Mukherjee R, et al. Matrix metalloproteinase-7 affects connexin-43 levels, electrical conduction, and survival after myocardial infarction. Circulation. 2006;113:2919–2928
  100. Furman C, Copin C, Kandoussi M, et al. Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability. Atherosclerosis. 2004;174:93–98
  101. Burke B, Giannoudis A, Corke KP, et al. Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy. Am J Pathol. 2003;163:1233–1243
  102. Busiek DF, Ross FP, McDonnell S, et al. The matrix metalloprotease matrilysin (PUMP) is expressed in developing human mononuclear phagocytes. J Biol Chem. 1992;267:9087–9092
  103. Busiek DF, Baragi V, Nehring LC, et al. Matrilysin expression by human mononuclear phagocytes and its regulation by cytokines and hormones. J Immunol. 1995;154:6484–6491
  104. Jormsjo S, Whatling C, Walter DH, et al. Allele-specific regulation of matrix metalloproteinase-7 promoter activity is associated with coronary artery luminal dimensions among hypercholesterolemic patients. Arterioscler Thromb Vasc Biol. 2001;21:1834–1839
  105. Rajavashisth TB, Xu XP, Jovinge S, et al. Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation. 1999;99:3103–3109
  106. Johnson JL, Sala-Newby GB, Ismail Y, et al. Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages. Arterioscler Thromb Vasc Biol. 2008;28:1647–1653
  107. Schneider F, Sukhova GK, Aikawa M, et al. Matrix-metalloproteinase-14 deficiency in bone-marrow-derived cells promotes collagen accumulation in mouse atherosclerotic plaques. Circulation. 2008;117:931–939
  108. Zhao H, Bernardo MM, Osenkowski P, et al. Differential inhibition of membrane type 3 (MT3)-matrix metalloproteinase (MMP) and MT1-MMP by tissue inhibitor of metalloproteinase (TIMP)-2 and TIMP-3 regulates pro-MMP-2 activation. J Biol Chem. 2004;279:8592–8601
  109. Feng M, Cai XJ, Zhang W, et al. Interleukin 6 enhances matrix metalloproteinase-14 expression via the Raf-Mek-Erk1/2-Ap-1 pathway. Clin Exp Pharmacol Physiol. 2010;in press
  110. Yu Y, Koike T, Kitajima S, et al. Temporal and quantitative analysis of expression of metalloproteinases (MMPs) and their endogenous inhibitors in atherosclerotic lesions. Histol Histopathol. 2008;23:1503–1516
  111. Chandler S, Cossins J, Lury J, et al. Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor-alpha fusion protein. Biochem Biophys Res Commun. 1996;228:421–429
  112. Hiller O, Lichte A, Oberpichler A, et al. Matrix metalloproteinases collagenase-2, macrophage elastase, collagenase-3, and membrane type 1-matrix metalloproteinase impair clotting by degradation of fibrinogen and factor XII. J Biol Chem. 2000;275:33008–33013
  113. Dong Z, Kumar R, Yang X, et al. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell. 1997;88:801–810
  114. Jormsjo S, Ye S, Moritz J, et al. Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ Res. 2000;86:998–1003
  115. Kumar R, Dong Z, Fidler IJ. Differential regulation of metalloelastase activity in murine peritoneal macrophages by granulocyte-macrophage colony-stimulating factor and macrophage colony-stimulating factor. J Immunol. 1996;157:5104–5111
  116. Feinberg MW, Jain MK, Werner F, et al. Transforming growth factor-beta 1 inhibits cytokine-mediated induction of human metalloelastase in macrophages. J Biol Chem. 2000;275:25766–25773
  117. Mitani H, Egashira K, Kimura M. HMG-CoA reductase inhibitor, fluvastatin, has cholesterol-lowering independent “direct” effects on atherosclerotic vessels in high cholesterol diet-fed rabbits. Pharmacol Res. 2003;48:417–427
  118. Souissi IJ, Billiet L, Cuaz-Perolin C, et al. Matrix metalloproteinase-12 gene regulation by a PPAR alpha agonist in human monocyte-derived macrophages. Exp Cell Res. 2008;314:3405–3414
  119. Luttun A, Lutgens E, Manderveld A, et al. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation. 2004;109:1408–1414
  120. Jguirim-Souissi I, Jelassi A, Addad F, et al. Plasma metalloproteinase-12 and tissue inhibitor of metalloproteinase-1 levels and presence, severity, and outcome of coronary artery disease. Am J Cardiol. 2007;100:23–27
  121. Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493–2503
  122. Nikkari ST, O'Brien KD, Ferguson M, et al. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation. 1995;92:1393–1398
  123. Sukhova GK, Schonbeck U, Rabkin E, et al. Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation. 1999;99:2503–2509
  124. Higashikata T, Yamagishi M, Higashi T, et al. Altered expression balance of matrix metalloproteinases and their inhibitors in human carotid plaque disruption: results of quantitative tissue analysis using real-time RT-PCR method. Atherosclerosis. 2006;185:165–172
  125. Nikkari ST, Geary RL, Hatsukami T, et al. Expression of collagen, interstitial collagenase, and tissue inhibitor of metalloproteinases-1 in restenosis after carotid endarterectomy. Am J Pathol. 1996;148:777–783
  126. Morgan AR, Rerkasem K, Gallagher PJ, et al. Differences in matrix metalloproteinase-1 and matrix metalloproteinase-12 transcript levels among carotid atherosclerotic plaques with different histopathological characteristics. Stroke. 2004;35:1310–1315
  127. Hasty KA, Pourmotabbed TF, Goldberg GI, et al. Human neutrophil collagenase. A distinct gene product with homology to other matrix metalloproteinases. J Biol Chem. 1990;265:11421–11424
  128. Dollery CM, Owen CA, Sukhova GK, et al. Neutrophil elastase in human atherosclerotic plaques: production by macrophages. Circulation. 2003;107:2829–2836
  129. Molloy KJ, Thompson MM, Jones JL, et al. Unstable carotid plaques exhibit raised matrix metalloproteinase-8 activity. Circulation. 2004;110:337–343
  130. Sluijter JP, Pulskens WP, Schoneveld AH, et al. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke. 2006;37:235–239
  131. Verhoeven B, Hellings WE, Moll FL, et al. Carotid atherosclerotic plaques in patients with transient ischemic attacks and stroke have unstable characteristics compared with plaques in asymptomatic and amaurosis fugax patients. J Vasc Surg. 2005;42:1075–1081
  132. Saren P, Welgus HG, Kovanen PT. TNF-alpha and IL-1beta selectively induce expression of 92-kDa gelatinase by human macrophages. J Immunol. 1996;157:4159–4165
  133. Galis ZS, Muszynski M, Sukhova GK, et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res. 1994;75:181–189
  134. Rydziel S, Varghese S, Canalis E. Transforming growth factor beta1 inhibits collagenase 3 expression by transcriptional and post-transcriptional mechanisms in osteoblast cultures. J Cell Physiol. 1997;170:145–152
  135. Lemaitre V, O'Byrne TK, Borczuk AC, et al. ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis. J Clin Invest. 2001;107:1227–1234
  136. Rutter JL, Mitchell TI, Buttice G, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res. 1998;58:5321–5325
  137. Kanamori Y, Matsushima M, Minaguchi T, et al. Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. Cancer Res. 1999;59:4225–4227
  138. Newby AC, Johnson JL. Genetic strategies to elucidate the roles of matrix metalloproteinases in atherosclerotic plaque growth and stability. Circ Res. 2005;97:958–960
  139. Momiyama Y, Ohmori R, Tanaka N, et al. High plasma levels of matrix metalloproteinase-8 in patients with unstable angina. Atherosclerosis. 2010;in press
  140. Nakamura H, Fujii Y, Inoki I, et al. Brevican is degraded by matrix metalloproteinases and aggrecanase-1 (ADAMTS4) at different sites. J Biol Chem. 2000;275:38885–38890
  141. Turk BE, Huang LL, Piro ET, et al. Determination of protease cleavage site motifs using mixture-based oriented peptide libraries. Nat Biotechnol. 2001;19:661–667
  142. Imai K, Hiramatsu A, Fukushima D, et al. Degradation of decorin by matrix metalloproteinases: identification of the cleavage sites, kinetic analyses and transforming growth factor-beta1 release. Biochem J. 1997;322(Pt 3):809–814
  143. Hanemaaijer R, Koolwijk P, le Clercq L, et al. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor alpha, interleukin 1 and phorbol ester. Biochem J. 1993;296(Pt 3):803–809
  144. Li Z, Li L, Zielke HR, et al. Increased expression of 72-kd type IV collagenase (MMP-2) in human aortic atherosclerotic lesions. Am J Pathol. 1996;148:121–128
  145. Kieffer P, Giummelly P, Schjoth B, et al. Activation of metalloproteinase-2, loss of matrix scleroprotein content and coronary artery calcification. Atherosclerosis. 2001;157:251–254
  146. de Nooijer R, Verkleij CJ, von der Thusen JH, et al. Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arterioscler Thromb Vasc Biol. 2006;26:340–346
  147. Choudhary S, Higgins CL, Chen IY, et al. Quantitation and localization of matrix metalloproteinases and their inhibitors in human carotid endarterectomy tissues. Arterioscler Thromb Vasc Biol. 2006;26:2351–2358
  148. Borregaard N, Sehested M, Nielsen BS, et al. Biosynthesis of granule proteins in normal human bone marrow cells. Gelatinase is a marker of terminal neutrophil differentiation. Blood. 1995;85:812–817
  149. Harvey MB, Leco KJ, Arcellana-Panlilio MY, et al. Proteinase expression in early mouse embryos is regulated by leukaemia inhibitory factor and epidermal growth factor. Development. 1995;121:1005–1014
  150. Janowska-Wieczorek A, Marquez LA, Nabholtz JM, et al. Growth factors and cytokines upregulate gelatinase expression in bone marrow CD34(+) cells and their transmigration through reconstituted basement membrane. Blood. 1999;93:3379–3390
  151. Witty JP, Foster SA, Stricklin GP, et al. Parathyroid hormone-induced resorption in fetal rat limb bones is associated with production of the metalloproteinases collagenase and gelatinase B. J Bone Miner Res. 1996;11:72–78
  152. Herman MP, Sukhova GK, Kisiel W, et al. Tissue factor pathway inhibitor-2 is a novel inhibitor of matrix metalloproteinases with implications for atherosclerosis. J Clin Invest. 2001;107:1117–1126
  153. Overall CM, Sodek J, Concanavalin A. produces a matrix-degradative phenotype in human fibroblasts. Induction and endogenous activation of collagenase, 72-kDa gelatinase, and Pump-1 is accompanied by the suppression of the tissue inhibitor of matrix metalloproteinases. J Biol Chem. 1990;265:21141–21151
  154. Overall CM, Wrana JL, Sodek J. Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-beta 1 in human fibroblasts. Comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression. J Biol Chem. 1991;266:14064–14071
  155. Ward RV, Atkinson SJ, Slocombe PM, et al. Tissue inhibitor of metalloproteinases-2 inhibits the activation of 72 kDa progelatinase by fibroblast membranes. Biochim Biophys Acta. 1991;1079:242–246
  156. Iredale JP, Murphy G, Hembry RM, et al. Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinases-1. Implications for regulation of matrix degradation in liver. J Clin Invest. 1992;90:282–287
  157. Bergmann U, Tuuttila A, Stetler-Stevenson WG, et al. Autolytic activation of recombinant human 72 kilodalton type IV collagenase. Biochemistry. 1995;34:2819–2825
  158. Strongin AY, Collier I, Bannikov G, et al. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem. 1995;270:5331–5338
  159. Hernandez-Barrantes S, Shimura Y, Soloway PD, et al. Differential roles of TIMP-4 and TIMP-2 in pro-MMP-2 activation by MT1-MMP. Biochem Biophys Res Commun. 2001;281:126–130
  160. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol. 2001;21:1104–1117
  161. Murphy G, Ward R, Hembry RM, et al. Characterization of gelatinase from pig polymorphonuclear leucocytes. A metalloproteinase resembling tumour type IV collagenase. Biochem J. 1989;258:463–472
  162. Nguyen M, Arkell J, Jackson CJ. Human endothelial gelatinases and angiogenesis. Int J Biochem Cell Biol. 2001;33:960–970
  163. Kolkenbrock H, Hecker-Kia A, Orgel D, et al. Progelatinase B forms from human neutrophils. complex formation of monomer/lipocalin with TIMP-1. Biol Chem. 1996;377:529–533
  164. Menashi S, Fridman R, Desrivieres S, et al. Regulation of 92-kDa gelatinase B activity in the extracellular matrix by tissue kallikrein. Ann N Y Acad Sci. 1994;732:466–468
  165. Ferry G, Lonchampt M, Pennel L, et al. Activation of MMP-9 by neutrophil elastase in an in vivo model of acute lung injury. FEBS Lett. 1997;402:111–115
  166. Kolkenbrock H, Orgel D, Hecker-Kia A, et al. Generation and activity of the ternary gelatinase B/TIMP-1/LMW-stromelysin-1 complex. Biol Chem Hoppe Seyler. 1995;376:495–500
  167. Bu CH, Pourmotabbed T. Mechanism of activation of human neutrophil gelatinase B. Discriminating between the role of Ca2+in activation and catalysis. J Biol Chem. 1995;270:18563–18569
  168. Howard EW, Bullen EC, Banda MJ. Preferential inhibition of 72-and 92-kDa gelatinases by tissue inhibitor of metalloproteinases-2. J Biol Chem. 1991;266:13070–13075
  169. Leber TM, Balkwill FR. Regulation of monocyte MMP-9 production by TNF-alpha and a tumour-derived soluble factor (MMPSF). Br J Cancer. 1998;78:724–732
  170. Kossakowska AE, Edwards DR, Prusinkiewicz C, et al. Interleukin-6 regulation of matrix metalloproteinase (MMP-2 and MMP-9) and tissue inhibitor of metalloproteinase (TIMP-1) expression in malignant non-Hodgkin's lymphomas. Blood. 1999;94:2080–2089
  171. Martin J, Eynstone L, Davies M, et al. Induction of metalloproteinases by glomerular mesangial cells stimulated by proteins of the extracellular matrix. J Am Soc Nephrol. 2001;12:88–96
  172. Wagsater D, Zhu C, Bjorck HM, et al. Effects of PDGF-C and PDGF-D on monocyte migration and MMP-2 and MMP-9 expression. Atherosclerosis. 2009;202:415–423
  173. Otero-Vinas M, Llorente-Cortes V, Pena E, et al. Aggregated low density lipoproteins decrease metalloproteinase-9 expression and activity in human coronary smooth muscle cells. Atherosclerosis. 2007;194:326–333
  174. Xu XP, Meisel SR, Ong JM, et al. Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation. 1999;99:993–998
  175. Kong YZ, Yu X, Tang JJ, et al. Macrophage migration inhibitory factor induces MMP-9 expression: implications for destabilization of human atherosclerotic plaques. Atherosclerosis. 2005;178:207–215
  176. Bu DX, Hemdahl AL, Gabrielsen A, et al. Induction of neutrophil gelatinase-associated lipocalin in vascular injury via activation of nuclear factor-kappaB. Am J Pathol. 2006;169:2245–2253
  177. Schmidt R, Bultmann A, Fischel S, et al. Extracellular matrix metalloproteinase inducer (CD147) is a novel receptor on platelets, activates platelets, and augments nuclear factor kappaB-dependent inflammation in monocytes. Circ Res. 2008;102:302–309
  178. Doronzo G, Russo I, Mattiello L, et al. C-reactive protein increases matrix metalloproteinase-2 expression and activity in cultured human vascular smooth muscle cells. J Lab Clin Med. 2005;146:287–298
  179. Schonbeck U, Mach F, Sukhova GK, et al. Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture?. Circ Res. 1997;81:448–454
  180. Choi EY, Kim D, Hong BK, et al. Upregulation of extracellular matrix metalloproteinase inducer (EMMPRIN) and gelatinases in human atherosclerosis infected with Chlamydia pneumoniae: the potential role of Chlamydia pneumoniae infection in the progression of atherosclerosis. Exp Mol Med. 2002;34:391–400
  181. Cipollone F, Fazia M, Iezzi A, et al. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation. 2004;109:1482–1488
  182. Shah PK, Falk E, Badimon JJ, et al. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation. 1995;92:1565–1569
  183. Kuzuya M, Nakamura K, Sasaki T, et al. Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. Arterioscler Thromb Vasc Biol. 2006;26:1120–1125
  184. Galis ZS, Johnson C, Godin D, et al. Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res. 2002;91:852–859
  185. Choi ET, Collins ET, Marine LA, et al. Matrix metalloproteinase-9 modulation by resident arterial cells is responsible for injury-induced accelerated atherosclerotic plaque development in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 2005;25:1020–1025
  186. Godin D, Ivan E, Johnson C, et al. Remodeling of carotid artery is associated with increased expression of matrix metalloproteinases in mouse blood flow cessation model. Circulation. 2000;102:2861–2866
  187. Lemaitre V, Kim HE, Forney-Prescott M, et al. Transgenic expression of matrix metalloproteinase-9 modulates collagen deposition in a mouse model of atherosclerosis. Atherosclerosis. 2008;
  188. Fernandez-Patron C, Martinez-Cuesta MA, Salas E, et al. Differential regulation of platelet aggregation by matrix metalloproteinases-9 and -2. Thromb Haemost. 1999;82:1730–1735
  189. Lelongt B, Bengatta S, Delauche M, et al. Matrix metalloproteinase 9 protects mice from anti-glomerular basement membrane nephritis through its fibrinolytic activity. J Exp Med. 2001;193:793–802
  190. Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem. 2001;276:7549–7558
  191. Zhang B, Henney A, Eriksson P, et al. Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Hum Genet. 1999;105:418–423
  192. Yasmin KM, McEniery CM, O'Shaughnessy KM, et al. Variation in the human matrix metalloproteinase-9 gene is associated with arterial stiffness in healthy individuals. Arterioscler Thromb Vasc Biol. 2006;26:1799–1805
  193. Bauters C, Lamblin N, Ennezat PV, et al. A prospective evaluation of left ventricular remodeling after inaugural anterior myocardial infarction as a function of gene polymorphisms in the renin-angiotensin-aldosterone, adrenergic, and metalloproteinase systems. Am Heart J. 2007;153:641–648
  194. Zhou S, Feely J, Spiers JP, et al. Matrix metalloproteinase-9 polymorphism contributes to blood pressure and arterial stiffness in essential hypertension. J Hum Hypertens. 2007;21:861–867
  195. Rauch I, Iglseder B, Paulweber B, et al. MMP-9 haplotypes and carotid artery atherosclerosis: an association study introducing a novel multicolour multiplex RealTime PCR protocol. Eur J Clin Invest. 2008;38:24–33
  196. Medley TL, Cole TJ, Dart AM, et al. Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arterioscler Thromb Vasc Biol. 2004;24:1479–1484
  197. Demacq C, de Souza AP, Machado AA, et al. Genetic polymorphism of matrix metalloproteinase (MMP)-9 does not affect plasma MMP-9 activity in healthy subjects. Clin Chim Acta. 2006;365:183–187
  198. Shimajiri S, Arima N, Tanimoto A, et al. Shortened microsatellite d(CA)21 sequence down-regulates promoter activity of matrix metalloproteinase 9 gene. FEBS Lett. 1999;455:70–74
  199. Fiotti N, Altamura N, Fisicaro M, et al. MMP-9 microsatellite polymorphism and susceptibility to carotid arteries atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26:1330–1336
  200. Zeng B, Prasan A, Fung KC, et al. Elevated circulating levels of matrix metalloproteinase-9 and -2 in patients with symptomatic coronary artery disease. Intern Med J. 2005;35:331–335
  201. Chin JR, Murphy G, Werb Z. Stromelysin, a connective tissue-degrading metalloendopeptidase secreted by stimulated rabbit synovial fibroblasts in parallel with collagenase. Biosynthesis, isolation, characterization, and substrates. J Biol Chem. 1985;260:12367–12376
  202. Noel A, Santavicca M, Stoll I, et al. Identification of structural determinants controlling human and mouse stromelysin-3 proteolytic activities. J Biol Chem. 1995;270:22866–22872
  203. Henney AM, Wakeley PR, Davies MJ, et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci U S A. 1991;88:8154–8158
  204. Galis ZS, Muszynski M, Sukhova GK, et al. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann N Y Acad Sci. 1995;748:501–507
  205. Montero I, Orbe J, Varo N, et al. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: implications for clinical and subclinical atherosclerosis. J Am Coll Cardiol. 2006;47:1369–1378
  206. Schonbeck U, Mach F, Sukhova GK, et al. Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo. J Exp Med. 1999;189:843–853
  207. Moilanen M, Sorsa T, Stenman M, et al. Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-3) and degrades type I collagen. Biochemistry. 2003;42:5414–5420
  208. Shapiro SD, Campbell EJ, Kobayashi DK, et al. Immune modulation of metalloproteinase production in human macrophages. Selective pretranslational suppression of interstitial collagenase and stromelysin biosynthesis by interferon-gamma. J Clin Invest. 1990;86:1204–1210
  209. Jeng AY, Chou M, Sawyer WK, et al. Enhanced expression of matrix metalloproteinase-3,-12, and-13 mRNAs in the aortas of apolipoprotein E-deficient mice with advanced atherosclerosis. Ann N Y Acad Sci. 1999;878:555–558
  210. Ye S, Eriksson P, Hamsten A, et al. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem. 1996;271:13055–13060
  211. Zhu C, Odeberg J, Hamsten A, et al. Allele-specific MMP-3 transcription under in vivo conditions. Biochem Biophys Res Commun. 2006;348:1150–1156
  212. Mattey DL, Nixon NB, Dawes PT, et al. Association of matrix metalloproteinase 3 promoter genotype with disease outcome in rheumatoid arthritis. Genes Immun. 2004;5:147–149
  213. Tsukahara S, Shinozaki M, Ikari K, et al. Effect of matrix metalloproteinase-3 functional SNP on serum matrix metalloproteinase-3 level and outcome measures in Japanese RA patients. Rheumatology (Oxford). 2008;47:41–44
  214. Samnegard A, Silveira A, Lundman P, et al. Serum matrix metalloproteinase-3 concentration is influenced by MMP-3-1612 5A/6A promoter genotype and associated with myocardial infarction. J Intern Med. 2005;258:411–419
  215. Ogata T, Shibamura H, Tromp G, et al. Genetic analysis of polymorphisms in biologically relevant candidate genes in patients with abdominal aortic aneurysms. J Vasc Surg. 2005;41:1036–1042
  216. Beaudeux JL, Giral P, Bruckert E, et al. Serum matrix metalloproteinase-3 and tissue inhibitor of metalloproteinases-1 as potential markers of carotid atherosclerosis in infraclinical hyperlipidemia. Atherosclerosis. 2003;169:139–146
  217. Wu TC, Leu HB, Lin WT, et al. Plasma matrix metalloproteinase-3 level is an independent prognostic factor in stable coronary artery disease. Eur J Clin Invest. 2005;35:537–545
  218. Noji Y, Kajinami K, Kawashiri MA, et al. Circulating matrix metalloproteinases and their inhibitors in premature coronary atherosclerosis. Clin Chem Lab Med. 2001;39:380–384
  219. Muller D, Quantin B, Gesnel MC, et al. The collagenase gene family in humans consists of at least four members. Biochem J. 1988;253:187–192
  220. Murphy G, Cockett MI, Ward RV, et al. Matrix metalloproteinase degradation of elastin, type IV collagen and proteoglycan. A quantitative comparison of the activities of 95 kDa and 72 kDa gelatinases, stromelysins-1 and -2 and punctuated metalloproteinase (PUMP). Biochem J. 1991;277(Pt 1):277–279
  221. Park HI, Turk BE, Gerkema FE, et al. Peptide substrate specificities and protein cleavage sites of human endometase/matrilysin-2/matrix metalloproteinase-26. J Biol Chem. 2002;277:35168–35175
  222. Baragi VM, Fliszar CJ, Conroy MC, et al. Contribution of the C-terminal domain of metalloproteinases to binding by tissue inhibitor of metalloproteinases. C-terminal truncated stromelysin and matrilysin exhibit equally compromised binding affinities as compared to full-length stromelysin. J Biol Chem. 1994;269:12692–12697
  223. Boixel C, Fontaine V, Rucker-Martin C, et al. Fibrosis of the left atria during progression of heart failure is associated with increased matrix metalloproteinases in the rat. J Am Coll Cardiol. 2003;42:336–344
  224. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature. 1994;370:61–65
  225. Ray BK, Shakya A, Turk JR, et al. Induction of the MMP-14 gene in macrophages of the atherosclerotic plaque: role of SAF-1 in the induction process. Circ Res. 2004;95:1082–1090
  226. Holmbeck K, Bianco P, Caterina J, et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell. 1999;99:81–92
  227. Chavey C, Mari B, Monthouel MN, et al. Matrix metalloproteinases are differentially expressed in adipose tissue during obesity and modulate adipocyte differentiation. J Biol Chem. 2003;278:11888–11896
  228. Skoog T, Ahokas K, Orsmark C, et al. MMP-21 is expressed by macrophages and fibroblasts in vivo and in culture. Exp Dermatol. 2006;15:775–783
  229. Velasco G, Pendas AM, Fueyo A, et al. Cloning and characterization of human MMP-23, a new matrix metalloproteinase predominantly expressed in reproductive tissues and lacking conserved domains in other family members. J Biol Chem. 1999;274:4570–4576
  230. Bernal F, Hartung HP, Kieseier BC. Tissue mRNA expression in rat of newly described matrix metalloproteinases. Biol Res. 2005;38:267–271
  231. Matsumoto S, Kobayashi T, Katoh M, et al. Expression and localization of matrix metalloproteinase-12 in the aorta of cholesterol-fed rabbits: relationship to lesion development. Am J Pathol. 1998;153:109–119
  232. Kangavari S, Matetzky S, Shah PK, et al. Smoking increases inflammation and metalloproteinase expression in human carotid atherosclerotic plaques. J Cardiovasc Pharmacol Ther. 2004;9:291–298
  233. Yamada S, Wang KY, Tanimoto A, et al. Matrix metalloproteinase 12 accelerates the initiation of atherosclerosis and stimulates the progression of fatty streaks to fibrous plaques in transgenic rabbits. Am J Pathol. 2008;172:1419–1429
  234. Liang J, Liu E, Yu Y, et al. Macrophage metalloelastase accelerates the progression of atherosclerosis in transgenic rabbits. Circulation. 2006;113:1993–2001
  235. Lamblin N, Bauters C, Hermant X, et al. Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J Am Coll Cardiol. 2002;40:43–48

 Statement of Conflict of Interest: see page 422.

PII: S0033-0620(09)00118-2

doi: 10.1016/j.pcad.2009.12.002

Progress in Cardiovascular Diseases
Volume 52, Issue 5 , Pages 410-428 , March 2010

Article Tools